NCT07681817Not yet recruiting
Risk Stratification and Proactive Nursing Intervention for Acute Kidney Injury Following Interventional Therapy in Patients With Liver Cancer
Source: ClinicalTrials.gov · Last updated 2 Jul 2026
Brief summary (registry, in English)
This study focuses on the early identification and precision prevention of acute kidney injury (AKI) following interventional therapy in patients with liver cancer. A prospective, phased mixed-methods research design will be adopted. In the first phase, a prospective cohort study will be conducted to systematically collect clinical and nursing-related data. A Super Learner ensemble algorithm will be employed to develop and validate an AKI risk prediction model, enabling precise risk stratification of patients. In the second phase, a prospective randomized controlled trial will be implemented. Guided by the Health Belief Model (HBM), a risk-stratified proactive nursing intervention will be delivered, and its effectiveness will be compared with that of routine nursing care in reducing the incidence of AKI, improving adherence to hydration protocols, optimizing the management of nephrotoxic medications, and enhancing patients' self-management capabilities. By integrating intelligent risk prediction with proactive nursing intervention strategies, this study aims to establish a reproducible and scalable precision prevention and management model for AKI in liver cancer patients undergoing interventional therapy. The findings are expected to provide scientific evidence for early AKI warning and proactive nursing practice, thereby promoting the precision, intelligence, and standardization of oncologic interventional nursing care.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- First submitted
- 23 Jun 2026
- Start date
- 1 Jul 2026
- Primary completion date
- 31 Dec 2027
- Lead sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT07681817
What you commit to
- Study type: Interventional
- Planned participants: 200
- From 1 Jul 2026 to the primary completion date, 31 Dec 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Development of AKI within 24 hours after interventional therapy according to KDIGO criteria
- Requirement for postoperative ICU admission and continuous life-support therapy
- Mandatory use of nephrotoxic medications that cannot be discontinued, substituted, or adjusted during the study period
Other illness
- Severe psychiatric disorders, cognitive impairment, or communication barriers preventing participation in HBM-based assessment or intervention
Other
- Participation in other clinical intervention studies that may affect renal function or nursing outcomes
Who the study is looking for
- Completed eligibility screening in Phase I of the study
- Completed AKI risk assessment using the established prediction model
- Classified by the model as at risk for AKI (moderate- or high-risk patients prioritized; low-risk patients included only for exploratory/observational analysis)
- Conscious and able to communicate effectively
- Able to understand and comply with nursing interventions
- Expected hospital stay of at least 3 days
- Available for postoperative follow-up
- Provided written informed consent jointly with a primary caregiver
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.